TECX Tectonic Therapeutic, Inc.
Financings ·
Tectonic's January 30, 2025 presentation put cash at $159 million as of September 30, 2024. On February 3 it agreed to a $185.0 million PIPE, with 3,689,465 shares sold at $50.00 each to funds and $54.14 each to officers and directors.
We have not published a story on Tectonic Therapeutic yet. When there is news, it will appear here.
Tectonic Therapeutic is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs). It uses a proprietary technology platform called GEODe, short for GPCRs Engineered for Optimal Discovery, to address the historical difficulty of drugging GPCRs with biologics. It focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent. Its lead asset, TX45, is an Fc-relaxin fusion molecule for Group 2 PH-HFpEF and Group 3 PH-ILD, the latter being pulmonary hypertension associated with interstitial lung disease. The TX45 APEX Phase 2 trial in Group 2 PH-HFpEF patients is ongoing. TX2100 is in a Phase 1a clinical trial in healthy volunteers. The company notes that greater than 30% of all approved drugs address GPCR targets, and that the vast majority of those drugs are small molecules whose targets are largely confined to a few GPCR subfamilies.
| Product or program | What it is | Stage |
|---|---|---|
| TX45 | Fc-relaxin fusion molecule for Group 2 PH-HFpEF and Group 3 PH-ILD | Phase 2 (APEX trial ongoing in Group 2 PH-HFpEF) |
| TX2100 | Candidate in a clinical trial in healthy volunteers | Phase 1a |
| GEODe platform | Proprietary platform for discovering GPCR-targeted therapeutic proteins and antibodies |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $63.5 million | $41.4 million |
| Net income (loss) | -$74.2 million | -$58.0 million |
| Cash from operations | -$60.1 million | -$59.1 million |
| Cash and equivalents | $253.8 million | $141.2 million |
Our latest story on this, dated Jan 30, 2025: "Tectonic cites $159 million cash runway, then agrees to $185.0 million private placement". The story links the filing or release it is based on. Read the story.
Tectonic Therapeutic, Inc. trades under the ticker TECX on NASDAQ.
Tectonic Therapeutic, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Tectonic Therapeutic, Inc. is 1681087. Its filings are on SEC EDGAR.
19,549,366 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Tectonic Therapeutic, Inc. under United States.
Our directory classifies Tectonic Therapeutic, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Tectonic Therapeutic, Inc. is US8789721086.
aibio.space lists Tectonic Therapeutic, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NY.
Tectonic Therapeutic is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs). It uses a proprietary technology platform called GEODe, short for GPCRs Engineered for Optimal Discovery, to address the historical difficulty of drugging GPCRs with biologics.
TX45: Fc-relaxin fusion molecule for Group 2 PH-HFpEF and Group 3 PH-ILD Stage: Phase 2 (APEX trial ongoing in Group 2 PH-HFpEF).
TX2100: Candidate in a clinical trial in healthy volunteers Stage: Phase 1a.
Tectonic Therapeutic, Inc. reported a net loss of $74.2 million for the fiscal year ended Dec 31, 2025, and used $60.1 million of cash in operations, per its annual report to the SEC.
$63.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio